Imricor Medical Systems (ASX:IMR) - Chair and CEO, Steve Wedan
Chair and CEO, Steve Wedan
Source: Imricor
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Imricor Medical Systems (IMR) announces enrolling two more customer sites in Berlin
  • The German Heart Centre Berlin and the Charité Medical University Virchow-Klinikum Campus are the latest institutions to adopt the company’s iCMR ablation solutions, bringing the total number Imricor sites to 13
  • Both institutions will use a lab at the German Heart Centre Berlin but will separately purchase the company’s catheters and other consumable products
  • The agreement has a term of three years with either party able to terminate it at any time
  • Shares have been trading 6.06 per cent higher today at $1.05 each

Imricor Medical Systems (IMR) has announced it has enrolled two more customer sites in Berlin.

The German Heart Centre Berlin and the Charité Medical University Virchow-Klinikum Campus are the latest institutions to adopt the company’s Interventional Cardiac Magnetic Resonance Imaging (iCMR) ablation solutions. This brings the total number of Imricor sites to 13.

The company specialises in MRI compatible products for cardiac ablation procedures. This is the process of inserting a thin, flexible tube called catheters into the veins or arteries which creates heat or cold energy to restore a normal heartbeat.

IMR signed an equipment purchase agreement with the German Heart Centre Berlin to outfit an existing CMR for iCMR procedures. Both institutions will then use the lab.

The institutions will both separately purchase Imricor’s catheters and other consumable devices.

The agreement has a term of three years and either party may terminate the agreement at any time.

Chair and CEO Steve Wedan said this is major step forward for the company.

“These sites have well-established facilities and programs like the MRI Core Lab and the CMR-Academy, and we look forward to growing and deepening our relationships and collaborations with them in the coming months and years.”

The company said this is a key strategic goal to grow the number of sites performing realtime iCMR cardiac ablation procedures in Europe. Planning is underway for procedures to commence in the first half of 2022.

Shares were trading 6.06 per cent higher today at $1.05 each at 12:35 pm AEDT.

IMR by the numbers
More From The Market Herald
Limeade (ASX:LME) - CEO, Henry Albrecht

" Limeade (ASX:LME) maintains FY21 financial guidance in quarterly report

Limeade (ASX:LME) has maintained its FY21 revenue guidance of $50 million to $53 million, but posted…
Sihayo Gold (ASX:SIH) - Executive Chairman, Colin Moorhead

" Sihayo Gold (ASX:SIH) secures further interim funding

Sihayo Gold (ASX:SIH) has secured interim funding from its shareholder, PT Saratoga Investama Sedaya Tbk.

" Alchemy Resources (ASX:ALY) commences aircore drilling at Karonie

Aircore drilling is underway at Alchemy Resources' (ASX:ALY) Karonie gold project 110 kilometres east of Kalgoorlie,…
Little Green Pharma (ASX:LGP) - Managing Director, Fleta Solomon

" Little Green Pharma (ASX:LGP) seeks to expand to Greece

Little Green Pharma (ASX:LGP) seeks to expand to Greece